Molbio Diagnostics launches chip-based RTPCR test for diagnosing HSV-1 and HSV-2

The Real Time PCR test works on the existing Truelab infrastructure and doesn’t require any additional setup and equipment to run the test, making it possible to test at resource-limited settings

Molbio Diagnostics has launched the Truenat HSV 1/2 for testing the Herpes Simplex Virus. The test is approved by CDSCO and can provide sample-to-test results in an hour’s time. The Real Time PCR test works on the existing Truelab infrastructure and doesn’t require any additional setup and equipment to run the test, making it possible to test at resource-limited settings.

Commenting on the launch, Sriram Natarajan, CEO, Founder, and Director, of Molbio Diagnostics, said, “HSV is an infectious disease that the world has been fighting for a long time. Testing for HSV infection can help to reduce infection rates by promoting education and awareness, as well as, to some extent, removing the stereotype associated with the disease. We at Molbio will continue to develop such products and technologies in order to ensure a more promising future in healthcare.’

Dr Chandrasekhar Nair, CTO, and Director, Molbio Diagnostics said, “HSV is rarely addressed, and currently there is no cure. So, as the first step in preventing the disease’s spread, we need an effective method of testing at the point of care that is both cost-effective and provides accurate test results. Molbio’s Truenat HSV1/2 can ensure an easy and accurate diagnosis of the infection and thus leading to timely initiation of the treatment.”

Truenat is a point-of-care portable, battery-operated, IoT-enabled, Real Time PCR platform with a sample-to-result time of less than 1 hour. The platform can test over 40 diseases, including COVID-19, TB, Hepatitis, HIV, HPV, Dengue, Malaria, etc.